Clinical Trial: A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Study of SHR-1179 Injection in Participants With Obesity

U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07826364) titled 'A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Study of SHR-1179 Injection in Participants With Obesity' on Sept. 04.

Brief Summary: This study is a single-center, randomized, double-blind, dose-escalation, placebo-parallel-controlled Phase I clinical trial. The primary objective is to evaluate the safety and tolerability of a single subcutaneous injection of SHR-1179 in obese participants. For the single-ascending-dose (SAD) part in obese participants, a total of 5 dose cohorts are planned for the single-dose escalation.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Body Weight Management...